Investigations into the molecular alterations in sarcomas have made substantial progress during the past decade. Classical linkage analysis and the direct sequencing of chromosomal translocation fusions have identified candidate genes in many different sarcomas. A large group of these genes participate in signal transduction pathways and represent potential sites of disease intervention with targeted therapies. This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway-neurofibromatosis-will also be discussed. Curr Opin Oncol 2001, 13:249-255 
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Gastrointestinal stromal tumors and c-Kit
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the gastrointestinal tract. For most patients, GISTs are incidentally discovered during endoscopic, surgical, or radiologic procedures; however, a subset of patients present with abdominal pain or gastrointestinal bleeding. The tumors originate most frequently in the stomach, small bowel, and mesentery; less frequent primary sites include the colon and gallbladder. Whereas the majority of GISTs are benign based on histologic criteria and observational studies, approximately 500 to 1000 cases of malignant GIST are encountered each year in the United States (Fletcher, Personal communication, February 2001) [1, 2] . Malignant GIST has a dire prognosis when it becomes surgically unresectable, because it is unresponsive to chemotherapy and radiotherapy [3] [4] [5] .
The cellular and molecular origins of GISTs have been revealed during the past several years. GISTs were previously misdiagnosed as smooth muscle tumors until immunohistochemical examinations revealed that GISTs uniformly expressed the c-KIT receptor tyrosine kinase (CD117), allowing distinction between GISTs and myogenic tumors [6] [7] [8] . Interestingly, a cell type in the gastrointestinal tract that expresses c-KIT and differentiates in a c-KIT/stem cell factor-dependent manner is the interstitial cells of Cajal (ICC), an innervated cell type responsible for peristalsis in the upper gastrointestinal tract. This finding has led to the hypothesis that GISTs are derived from an ICC progenitor cell compartment, and GISTs, like ICC, are dependent upon c-KIT signaling [9] [10] [11] .
To investigate the nature of c-KIT signaling in GIST, Hirota et al.
[12•] sequenced the c-Kit gene in six malignant GISTs and identified juxtamembrane c-Kit mutations in five cases. These mutant c-Kit alleles were constitutively active and oncogenic. Activating c-Kit mutations have been identified in other neoplastic and myeloproliferative disorders, including germ cell tumors, mast cell tumors, agnogenic myeloid metaplasia and myelofibrosis, and chronic myelogenous leukemia [13] [14] [15] . In GIST, the majority of c-Kit activating mutations have been identified in the exon 11 juxtamembrane region, with less common extracellular (exon 9) and proximal tyrosine kinase domain mutations (exon 13) reported [16] . The reported frequency of activating c-Kit mutations in GIST is 21 to 57%, which is likely an 249 Indeed, the first reported GIST patient treated with STI571 had a remarkable response. The patient was a 50-year-old woman with metastatic GIST who had been previously treated with multiple surgical procedures and unsuccessful systemic treatments including MAID (mesna, doxorubicin, ifosfamide, and dacarbazine), who presented to her oncologist with progressive liver and mesenteric metastases. The c-Kit gene expressed by this patient's GIST was an activating deletion in exon 11. Treatment with oral STI571 at 400 mg per day was initiated, resulting in immediate symptomatic improvement. Radiologic examination with magnetic resonance imaging (MRI), dynamic MRI, and positron-emission tomography demonstrated significant reduction and alteration in tumor size and character, beginning at the earliest re-evaluation time of 2 weeks. Pathologic evaluation of biopsies from liver metastases obtained 1 and 2 months after the beginning of therapy revealed extensive replacement with myxoid degeneration and only rare cells expressing c-KIT. The patient has had a durable improvement in her performance status from 1 to 0 during the 13 months that she has been treated with STI571. Additionally, she has had no significant adverse events during treatment, with only mild transient nausea, muscle cramps, transient pedal edema, and increased frequency of bowel movements reported [30••]. The dramatic response of this patient to STI571 stimulated the launching of several international trials to extensively evaluate the effectiveness of this molecularly targeted therapy in GIST.
Signal transduction pathways in sarcoma as targets for therapeutic intervention

Inflammatory myofibroblastic tumor and ALK
Inflammatory myofibroblastic tumors (IMTs) are a clinicopathologically distinctive group of tumors, whichuntil recently-were thought to be benign lesions. They originate typically in the soft tissues, but occasionally in bone, and are composed of spindled mesenchymal cells admixed with a striking inflammatory infiltrate in which lymphocytes and plasma cells are predominant [31, 32] . In keeping with the inflammatory component, patients can present with constitutional signs-including fever, weight loss, and anemia-but in other cases, IMTs present as painless masses or incidental radiologic findings. . This finding represents the first scenario where an identical fusion oncogene has been found in mesenchymal and lymphoid neoplasia, but perhaps these findings are not surprising given the close embryologic relationship between mesenchymal and hematologic progenitors. Importantly, these findings suggest that biologically rational therapies for leukemias and lymphomas may, in some cases, have application in patients with sarcomas. Specifically, it is likely that inhibition of constitutively active ALK oncoproteins may be effective in the occasional IMT that progresses to high-grade sarcoma.
Congenital fibrosarcoma and congenital mesoblastic nephroma, and NTRK3
Congenital fibrosarcoma and congenital mesoblastic nephroma are closely related neoplasms originating in the soft tissues and kidney, respectively. Although defined originally as different tumor entities, they share many clinicopathologic and molecular cytogenetic features. Both are low-grade spindle cell proliferations that often progress to a cellular high-grade form in which the spindled cells become rounder and highly mitotic. Despite the high-grade appearance in the cellular tumors, prognosis is excellent. Surgical excision is often curative, and many inoperable lesions respond dramatically and completely to combination chemotherapy; however, the occasional treatment-refractory tumors can progress in a rapid and lethal manner.
The related pathogenesis of congenital fibrosarcoma and congenital mesoblastic nephroma was suggested originally by their similar cytogenetic profile, particularly trisomy 11, and by their often indistinguishable histopathologic appearance [38, 39] . This idea was confirmed by the realization that these entities contain an identical fusion oncogene, resulting from a translocation of chromosomes 12 and 15 and creating a fusion between the TEL (or ETV6) and NTRK3 genes [40-42]. The TEL-NTRK3 oncogene encodes a fusion oncoprotein in which the TEL helix-loop-helix domain drives constitutive activation of the NRTK3 tyrosine kinase domain, another example of a receptor tyrosine kinase fusion oncoprotein in which the usual N-terminal portion of the receptor (ie, the extracellular portion) is replaced with an ectopic oligomerization domain. The resultant fusion protein self associates constitutively, leading to activation of the NTRK3 cytoplasmic kinase domain in a growth factor-independent manner. Whereas the TEL-NTRK3 oncogene is expressed in most congenital fibrosarcoma and congenital mesoblastic nephroma, it has not been detected in other pediatric spindle cell tumors that can be histologic mimics [43•]. Initial studies suggest that oncogenic NTRK3 activation is an early, and perhaps initiating, event in congenital fibrosarcoma and congenital mesoblastic nephroma; therefore, pharmacologic inhibition of this kinase oncoprotein will likely provide an effective therapeutic option in the subset of children whose tumors are refractory to conventional therapies. In addition, characterization of the cell signaling pathways downstream of the NTRK3 oncoprotein will undoubtedly reveal additional activated targets suitable for pharmacologic inhibition [44•].
Dermatofibrosarcoma protuberans and platelet-derived growth factor alpha
Dermatofibrosarcoma protuberans is a low-grade spindle cell tumor that is generally subcutaneous and can undergo progression to high-grade sarcoma. The lowergrade forms are primarily managed surgically, and metastases are uncommon-although local recurrence is not infrequent. Higher-grade, fibrosarcomatous, forms can metastasize widely. Most dermatofibrosarcoma protuberans contain a translocation of chromosomes 17 and 22, resulting in oncogenic juxtaposition of the COL1A1 and platelet-derived growth factor beta (PDGFβ) genes [45, 46] . The oncogenic mechanism is interesting in that the COL1A1 promoter mediates high-level expression of PDGFβ transcripts whose coding sequence is normal.
PDGFβ serves as a ligand for both types of plateletderived growth factor receptors (PDGFRα and PDGFRβ), and it remains to be determined which-if not both-of these receptors communicates the oncogenic signal in dermatofibrosarcoma protuberans. Notably, the STI571 tyrosine kinase inhibitor has high activity against PDGFRα and PDGFRβ [47] and may therefore represent an important therapeutic tool in patients with higher-grade or metastatic dermatofibrosarcoma protuberans.
Desmoplastic small round cell tumor and platelet-derived growth factor alpha
Desmoplastic small round cell tumors are clinically aggressive and chemotherapy-resistant neoplasms that originate predominantly, but not exclusively, from intraabdominal soft tissues [48] . Virtually all of these tumors express an EWS-WT1 fusion oncogene [49] . The EWS-WT1 results from a translocation between the chromosome 11 short arm and the chromosome 22 long arm, juxtaposing the WT1 (Wilms tumor) and EWS (Ewing) genes, respectively [50]. The key histologic feature of this tumor is the admixture of small round neoplastic cells within an exuberant proliferation of reactive fibroblastic cells [49] . Notably, the EWS-WT1 oncoprotein, expressed in the neoplastic small round cells, is a transcriptional regulator that induces expression of PDGFα [51] . PDGFα is a ligand that binds and activates PDGFRα and PDGFRβ, the latter serving to activate potent mitogenic signaling pathways in fibroblasts [52] ; therefore, it is likely that oncogenically induced PDGFα expression partly accounts for the prominent desmoplastic reaction in these tumors. It is unclear, however, whether PDGFα also serves an autocrine or paracrine function in directly stimulating growth of the neoplastic cells. Irrespective, therapeutic intervention with plateletderived growth factor receptor inhibitors, such as STI571, might be expected to reduce tumor volume, particularly if the desmoplastic component proves essential for viability of the neoplastic cells.
Neurofibromatosis and Ras
Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome affecting 1 in 3500 people worldwide [53,54•] . Patients with NF1 develop multiple benign peripheral nerve sheath tumors, termed neurofibromas, which are often debilitating and can progress to malignant peripheral nerve sheath tumors (MPNSTs). Neurofibromas originate in a superficial dermal distribution or internally along the plexus of major nerves, and the plexiform neurofibromas are uniquely predisposed to malignant progression [55] . Additionally, NF1 patients are also predisposed to developing other malignancies, including astrocytic brain tumors, juvenile chronic myelomonocytic leukemia (JCMML), and pheochromocytoma [56] .
Pathologic and molecular investigations have provided insight into the development of NF1. Neurofibromas are heterogeneous lesions histologically, with an abundance of Schwann cells and perineurial cells, and entrapped nerve fibers. In contrast, MPNSTs, which originate from a subset of neurofibromas, are primarily composed of Schwann cells, suggesting the malignant potential of this cell type [55] . The genetic basis of NF1 was proposed with the identification of the NF1 gene in 1990 in kindreds affected with this disease [57] [58] [59] . Furthermore, tumors were shown to contain mutations in the remaining wild-type NF1 allele, suggesting that NF1 functions as a tumor suppressor gene [60] [61] [62] [63] . Disruption of the normal NF1 allele, a process termed loss of heterozygosity, was also identified in Schwann cells from neurofibromas and MPNSTs, supporting the central role of Schwann cells in these lesions [64•,65•].
The NF1 gene encodes a large protein, known as neurofibromin, with a region of similarity to the p120 Ras GTPase activating protein (Ras-GAP) and the yeast Ras-GAP proteins IRA1 and IRA2 [66, 67] . Ras-GAP proteins attenuate signaling through the Ras pathway by stimulating the hydrolysis of GTP in Ras-GTP complexes, producing the inactive Ras-GDP complex. Neurofibromin has been shown to act as a Ras-GAP by interacting with Ras-GTP in vitro and by complementation studies of mutant yeast strains deficient in IRA proteins [68, 69] . Importantly, Ras-GTP levels were found to be increased in multiple tumor types containing NF1 mutations [70] [71] [72] [73] . Furthermore, a subset of familial NF1 mutations are point mutations that result in the loss of Ras binding or Ras-GAP activity [74] . Finally, a subset of JCMML patients have either NF1 mutations or oncogenic mutations of N-ras, suggesting that dysregulation of the Ras pathway per se is an important step in the pathobiology of JCMML [74] . Collectively, these results suggest that aberrant signaling through the Ras pathway may be central to the pathogenesis of NF1.
The discovery of increased Ras activation in NF1 presents several potential avenues for therapeutic intervention in this disease, because currently, there is no way to replace neurofibromin function in NF1 tumors. Active Ras-GTP complexes interact with multiple effector signaling pathways and elicit a myriad of biological effects. The major downstream effector pathways of Ras-GTP include PI3 kinase, Raf kinase, and Ral-GDS, and previous work has implicated these pathways in cellular proliferation, survival, and differentiation [75] .
The first potential site of intervention would be to target Ras itself. Farnesyl protein transferase inhibitors (FTIs) are peptidomimetics designed to inhibit the farnesylation of Ras and thus prevent the proper trafficking of Ras to the plasma membrane [76, 77] . Currently, there are several phase 1 trials evaluating the safety of FTIs in patients with carcinomas, and it will be exciting to test this possibility in the future; however, Ras proteins may also be geranylated and still be targeted to the membrane [76, 77] . Other anti-ras strategies, such as ribozyme therapies [78] , are specific for mutant ras, and although N-ras mutations and NF1 deletions may be interchangeable in JCMML [74] , ras mutations have not been detected in NF1. The effector pathways of ras offer alternative targets for intervention, and inhibitors of PI3K and MEK are currently being evaluated in preclinical and clinical studies in other malignancies [79, 80] .
Conclusions
Determination of the molecular mechanisms involved in different sarcomas (Table 1 ) may now have a direct consequence in improving patient care with the addition of molecularly targeted therapies. The selectivity and efficacy of small molecules such as STI571 achieve a therapeutic index far superior to conventional chemotherapy and allow for daily oral administration in GIST. In addition to GIST, other sarcomas may also be responsive to STI571, such as dermatofibrosarcoma protuberans and desmoplastic small round cell tumor. Furthermore, anti-ras therapies are sensible strategies to evaluate in NF1 and MPNST. Sarcomas with aberrant signaling through ALK and NTRK3 await the availability of specific antagonists.
Signal transduction pathway inhibitors represent a substantial advance in oncology. The successful treatment of CML and now GIST with STI571 supports the idea that therapies directed against the molecular mechanisms involved in the initiation and maintenance of tumor cells will likely be more effective than conventional cytotoxic agents and provides impetus for the discovery and development of additional agents for use in other cancers. Alternative methods to target signal transduction pathways include monoclonal antibodies directed against extracellular proteins and antisense and ribozyme agents that target specific mRNA species. A combination of approaches that includes small molecules and other therapies directed against specific signaling pathways will be useful alternatives and additions to cytotoxic chemotherapy in the future.
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